SCHEMBL653271

SCHEMBL653271

O=C(CC(=O)c1ccccn1)c1ccc2c(c1)OCCO2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 11/20 1.00
WNT3A P56704 7/20 0.62
RAB9A P51151 7/20 0.61
NPC1 O15118 6/20 0.61
SMN1; SMN2 Q16637 5/20 0.61
PKM P14618 2/20 0.61
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56
MAPT P10636 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
KDM4E B2RXH2 1/20 0.56
ATM Q13315 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL654355 0.90 CTNNB1 (1.00) CTNNB1WNT3APKM
SCHEMBL17190804 0.84 CTNNB1 (0.72) CTNNB1WNT3ARAB9ANPC1SMN1; SMN2
SCHEMBL10027735 0.82 CTNNB1 (0.82) CTNNB1WNT3ARAB9ANPC1SMN1; SMN2
SCHEMBL15979891 0.82 CTNNB1 (0.85) CTNNB1WNT3ARAB9ANPC1SMN1; SMN2
SCHEMBL5695788 0.80 CTNNB1 (0.67) CTNNB1WNT3ARAB9ANPC1SMN1; SMN2
SCHEMBL11617713 0.80 CTNNB1 (0.67) CTNNB1WNT3ARAB9ANPC1SMN1; SMN2
SCHEMBL15969289 0.77 CTNNB1 (1.00) CTNNB1WNT3APKM
SCHEMBL15979765 0.77 CTNNB1 (0.72) CTNNB1WNT3A
SCHEMBL29355245 0.76 CES2 (0.64) CTNNB1WNT3ASMN1; SMN2KMT2AALDH1A1
SCHEMBL253276 0.76 CES2 (0.64) CTNNB1WNT3ASMN1; SMN2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3915367-A1 DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS BioSplice Therapeutics, Inc. (US) 2021-12-01 EP disclosed
EP-3915367-A1 DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS BioSplice Therapeutics, Inc. (US) 2021-12-01 EP disclosed
US-20210353604-A1 ß- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ ß -CATENIN SIGNALING PATHWAY ACTIVATORS VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2021-11-18 US disclosed
US-20210353604-A1 ß- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ ß -CATENIN SIGNALING PATHWAY ACTIVATORS VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2021-11-18 US disclosed
US-20200121663-A1 B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS WINTHERIX LLC 2020-04-23 US disclosed
US-20200121663-A1 B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS WINTHERIX LLC 2020-04-23 US disclosed
US-10314832-B2 β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators SAMUMED, LLC (US) 2019-06-11 US disclosed
US-10314832-B2 β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators SAMUMED, LLC (US) 2019-06-11 US disclosed
US-20180333400-A1 B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2018-11-22 US disclosed
EP-3311666-A1 DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS Samumed, LLC (US) 2018-04-25 EP disclosed
US-20140080902-A1 B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS SAMUMED, LLC (US) 2014-03-20 US disclosed
US-8629176-B1 β- and γ-diketones and γ-hydroxyketones as WNT/ β-catenin signaling pathway activators SAMUMED, LLC (US) 2014-01-14 US disclosed
US-8629176-B1 β- and γ-diketones and γ-hydroxyketones as WNT/ β-catenin signaling pathway activators SAMUMED, LLC (US) 2014-01-14 US disclosed
US-8629176-B1 β- and γ-diketones and γ-hydroxyketones as WNT/ β-catenin signaling pathway activators SAMUMED, LLC (US) 2014-01-14 US disclosed
US-20140005228-A1 B- AND Y -DIKETONES AND Y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS SAMUMED, LLC (US) 2014-01-02 US disclosed
US-8609717-B2 β- and γ-diketones and γ-hydroxyketones as WNT/β-catenin signaling pathway activators SAMUMED, LLC (US) 2013-12-17 US disclosed
WO-2012024404-A1 DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS WINTHERIX, LLC (US) 2012-02-23 WO disclosed
US-20120046320-A1 BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS WINTHERIX, LLC (US) 2012-02-23 US disclosed
US-20120046320-A1 BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS WINTHERIX, LLC (US) 2012-02-23 US disclosed
US-20120046320-A1 BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS WINTHERIX, LLC (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080902-A1 B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3B, WNT3A, GSK3A CTNNB1 6/4885WNT3A 2/4885RAB9A 938/4885
US-20210353604-A1 ß- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ ß -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 CTNNB1 6/4885WNT3A 4/4885RAB9A 1237/4885
US-20140005228-A1 B- AND Y -DIKETONES AND Y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3B, WNT3A, GSK3A CTNNB1 6/4885WNT3A 2/4885RAB9A 938/4885
US-20200121663-A1 B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3B, GSK3A, WNT3A CTNNB1 7/4885WNT3A 3/4885RAB9A 917/4885
US-20120046320-A1 BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS WNT1, CTNNA1, WNT3A CTNNB1 6/4885WNT3A 3/4885RAB9A 1168/4885
US-20180333400-A1 B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3B, GSK3A, WNT3A CTNNB1 7/4885WNT3A 3/4885RAB9A 917/4885
US-10314832-B2 β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators WNT1, GSK3A, GSK3B CTNNB1 5/4885WNT3A 4/4885RAB9A 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.